Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr files Seasonique

Executive Summary

Barr files NDA for 91-day extended regimen oral contraceptive Seasonique (84 tablets of 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven tablets of 0.01 mg ethinyl estradiol) in early October, the company said on its quarterly earnings call Nov. 4. Barr already markets Seasonale (84 tablets 0.15 mg levonorgestrel/0.03 ethinyl estradiol; seven inert tablets). "We have chosen the name Seasonique to leverage the very favorable reception our Seasonale product has received in the marketplace and to connote that it is part of a family of products in this area," CEO Bruce Downey said. Seasonique was previously referred to as DP3; the company is also developing lower-dose Seasonale Ultra-Lo...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS044923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel